Literatur
Appel BE, Chen L, Buxton AB et al (2016) Minimal treatment of low-risk, pediatric lymphocyte-predominant Hodgkin Lymphoma: A report from the Children’s Oncology Group. J Clin Oncol 34:2372–2379
Arber DA, Orazi A, Hasserjian R (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391–2405
Mauz-Körholz C, Gorde-Grosjean S, Hasenclever D et al (2007) Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma. Cancer 110:179–185
Shankar A, Hall GW, Gorde-Grosjean S et al (2012) Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodularlymphocyte predominant Hodgkin’slymphoma – an Anglo-French collaborative report. Eur J Cancer 48:1700–1706
Shankar AG, Kirkwood AA, Depani S et al (2016) Relapsed or poorly responsive nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents – a report from the United Kingdom’s Children’s Cancer and Leukaemia Study Group. Br J Haematol 173:421–431
Fan Z, Natkunam Y, Bair E et al (2003) Characterization of variant patterns of nodular lymphocyte predominant Hodgkin lymphoma with immunohistologic and clinicalcorrelation. Am J Surg Pathol 27:1346–1356
Boudová L, Torlakovic E, Delabie J et al (2003) Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T‑cell/histiocyte-rich B‑cell lymphoma: differential diagnosis between nodular lymphocyte predominant Hodgkin lymphoma and T‑cell/histiocyte-rich B‑cell lymphoma. Blood 102:3753–3758
Hartmann S, Eichenauer DA, Plütschow A et al (2013) The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report fromthe German Hodgkin Study Group (GHSG). Blood 122:4246–4252
Schellong G, Pötter R, Brämswig J et al (1999) High cure rates and reduced long-term toxicity in pediatric Hodgkin’s disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin’s Disease Study Group. J Clin Oncol 17:3736–3744
Dörffel W, Rühl U, Lüders H et al (2013) Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95. J Clin Oncol 31:1562–1568
Mauz-Körholz C, Hasenclever D, Dörffel W et al (2010) Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin’s lymphoma: the GPOH-HD-2002 study. J Clin Oncol 28:3680–3686
Advani RH, Horning SJ, Hoppe RT et al (2014) Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol 32:912–918
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
G. Mann und W. Holter geben an, dass kein Interessenkonflikt besteht.
Additional information
Originalpublikation Appel BE, Chen L, Buxton AB et al (2016) Minimal treatment of low-risk, pediatric lymphocyte-predominant Hodgkin lymphoma: a report from the Children’s Oncology Group. J Clin Oncol pii: JCO653469 [1]
Rights and permissions
About this article
Cite this article
Mann, G., Holter, W. Therapie des lokalisierten nodulären Lymphozyten-prädominanten Hodgkin-Lymphoms bei Kindern. Strahlenther Onkol 192, 827–829 (2016). https://doi.org/10.1007/s00066-016-1044-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00066-016-1044-2